# Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

> **NCT00642512** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Chemotherapy Induced Nausea and Vomiting

## Interventions

- **DRUG:** dronabinol
- **DRUG:** ondansetron
- **DRUG:** dronabinol/ondansetron
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00642512
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2008-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642512, "Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00642512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*